vimarsana.com

Latest Breaking News On - Sustained drug delivery technology - Page 1 : vimarsana.com

PolyActiva to Present Positive Clinical Trial Results at the 2022 American Glaucoma Society Annual Meeting

/PRNewswire/ PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with.

PolyActiva to Present Positive Clinical Trial Results at the 2022 American Glaucoma Society Annual Meeting

/PRNewswire/ PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with.

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.